Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

384 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Highlights from 2022 in EHJ Open.
Bäck M, Banach M, Braunschweig F, De Rosa S, Gimelli A, Kahan T, Ketelhuth DFJ, Lancellotti P, Larsson SC, Mellbin L, Nagy E, Savarese G, Szummer K, Wahl D; European Heart Journal Open Section Editors. Bäck M, et al. Among authors: savarese g. Eur Heart J Open. 2022 Dec 30;2(6):oeac084. doi: 10.1093/ehjopen/oeac084. eCollection 2022 Nov. Eur Heart J Open. 2022. PMID: 36600883 Free PMC article. No abstract available.
Association Between Use of Primary-Prevention Implantable Cardioverter-Defibrillators and Mortality in Patients With Heart Failure: A Prospective Propensity Score-Matched Analysis From the Swedish Heart Failure Registry.
Schrage B, Uijl A, Benson L, Westermann D, Ståhlberg M, Stolfo D, Dahlström U, Linde C, Braunschweig F, Savarese G. Schrage B, et al. Among authors: savarese g. Circulation. 2019 Nov 5;140(19):1530-1539. doi: 10.1161/CIRCULATIONAHA.119.043012. Epub 2019 Sep 3. Circulation. 2019. PMID: 31476893
Response by Schrage et al to Letter Regarding Article, "Association Between Use of Primary-Prevention Implantable Cardioverter-Defibrillators and Mortality in Patients With Heart Failure: A Prospective Propensity Score-Matched Analysis From the Swedish Heart Failure Registry".
Schrage B, Linde C, Braunschweig F, Savarese G. Schrage B, et al. Among authors: savarese g. Circulation. 2020 Mar 17;141(11):e648-e649. doi: 10.1161/CIRCULATIONAHA.120.045603. Epub 2020 Mar 16. Circulation. 2020. PMID: 32176544 No abstract available.
Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry.
Becher PM, Schrage B, Ferrannini G, Benson L, Butler J, Carrero JJ, Cosentino F, Dahlström U, Mellbin L, Rosano GMC, Sinagra G, Stolfo D, Lund LH, Savarese G. Becher PM, et al. Among authors: savarese g. Eur J Heart Fail. 2021 Jun;23(6):1012-1022. doi: 10.1002/ejhf.2131. Epub 2021 Mar 2. Eur J Heart Fail. 2021. PMID: 33599357 Free article.
Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter 2 inhibitors.
Herrington WG, Savarese G, Haynes R, Marx N, Mellbin L, Lund LH, Dendale P, Seferovic P, Rosano G, Staplin N, Baigent C, Cosentino F. Herrington WG, et al. Among authors: savarese g. Eur J Heart Fail. 2021 Aug;23(8):1260-1275. doi: 10.1002/ejhf.2286. Epub 2021 Jul 20. Eur J Heart Fail. 2021. PMID: 34184823 Free article. Clinical Trial.
Predictors of primary prevention implantable cardioverter-defibrillator use in heart failure with reduced ejection fraction: impact of the predicted risk of sudden cardiac death and all-cause mortality.
Schrage B, Lund LH, Benson L, Dahlström U, Shadman R, Linde C, Braunschweig F, Levy WC, Savarese G. Schrage B, et al. Among authors: savarese g. Eur J Heart Fail. 2022 Jul;24(7):1212-1222. doi: 10.1002/ejhf.2530. Epub 2022 May 22. Eur J Heart Fail. 2022. PMID: 35502681 Free PMC article.
384 results